Gilead Sciences (GILD) Research & Development (2009 - 2026)

Gilead Sciences (GILD) has reported Research & Development for 18 consecutive years, with $1.4 billion the latest figure, recorded in Q1 2026.

• Research & Development for Q1 2026 came in at $1.4 billion, down 0.51% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.8 billion (changed 0.47% YoY), and the FY2025 annual result was $5.8 billion, down 1.83% from the prior year.
• Research & Development was $1.4 billion for Q1 2026 at Gilead Sciences, down from $1.6 billion in the prior quarter.
• Over five years, Research & Development peaked at $1.6 billion in Q4 2024 and troughed at $1.1 billion in Q2 2022.
• Average Research & Development over 5 years is $1.4 billion, with a median of $1.4 billion recorded in 2023.
• Year-over-year, Research & Development advanced 27.68% in 2023 and dropped 9.28% in 2025.
• Over 5 years, Research & Development stood at $1.5 billion in 2022, then fell by 9.04% to $1.4 billion in 2023, then rose by 16.55% to $1.6 billion in 2024, then fell by 3.47% to $1.6 billion in 2025, then dropped by 13.38% to $1.4 billion in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $1.4 billion in Q1 2026, $1.6 billion in Q4 2025, and $1.3 billion in Q3 2025.